{"entity":{"id":"nct07105215","kind":"trial","name":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of RC278 in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.","summary":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors is a phase 1/2 interventional study registered as NCT07105215 by RemeGen Co., Ltd., with 312 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-12-31. Interventions recorded: RC278.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07105215","url":"https://clinicaltrials.gov/study/NCT07105215"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07105215","phase":"1/2","setting":"A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC278 for Injection in the Treatment of Locally Advanced Unresectable or Metastatic Malignant Solid Tumor","sponsor":"RemeGen Co., Ltd.","enrolled":312,"outcomes":[]},"route":"/trials/nct07105215/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}]}}